TrialHeart and vessels2014

Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.

Toru Miyoshi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.